8-K: Inspire Veterinary Partners Fights Nasdaq Delisting

Inspire Veterinary Partners, Inc. received a Nasdaq delisting notice due to minimum bid price non-compliance but has appealed the decision, staying immediate suspension.

Summary

• Inspire Veterinary Partners, Inc. (the Company) received a notice from Nasdaq on November 17, 2025, indicating non-compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
• The non-compliance was based on the closing bid price of the Company's common stock for 30 consecutive business days.
• Nasdaq informed the Company that its securities would be suspended from trading on The Nasdaq Capital Market at the opening of business on November 24, 2025, and a Form 25-NSE would be filed to remove its listing and registration.
• The Company requested an appeal to Nasdaq's Hearings Panel by November 20, 2025, which stays any further suspension or delisting action pending the hearing process.
• A hearing is scheduled for January 13, 2026.
• There is no assurance that the Panel will grant the Company's request for continued listing or that the Company will regain and maintain compliance.

Sentiment

Score: 3

Explanation: The filing indicates a significant negative event (delisting notice) and ongoing uncertainty, despite the temporary stay of delisting. The core issue of low stock price remains unresolved.

Positives

• The Company successfully requested a hearing before Nasdaq's Hearings Panel, which temporarily stays the suspension and delisting action.

Negatives

• Received a notice of non-compliance with Nasdaq's minimum bid price requirement (Rule 5550(a)(2)).
• Faces potential delisting from The Nasdaq Capital Market.
• The Company's common stock bid price has been below the required minimum for 30 consecutive business days.

Risks

• Potential delisting of common stock from The Nasdaq Capital Market if the appeal is unsuccessful or if the Company fails to regain compliance.
• Uncertainty regarding the outcome of the hearing before Nasdaq's Hearings Panel.
• Inability to regain compliance with Nasdaq's minimum bid price requirement.

Future Outlook

The Company's future listing on Nasdaq is uncertain and depends on the outcome of the scheduled hearing on January 13, 2026, and its ability to subsequently regain and maintain compliance with Nasdaq's listing standards.

Management Comments

• The Company requested a hearing before the prescribed date, which request will stay any further suspension or delisting action by Nasdaq pending the ultimate conclusion of the hearing process.
• There can be no assurance that the Panel will grant the Company's request for continued listing or that the Company will be able to regain compliance and thereafter maintain its listing on Nasdaq.

Industry Context

This announcement is specific to Inspire Veterinary Partners' listing status and does not directly provide information on broader trends within the veterinary services industry or competitive landscape.

Stakeholder Impact

• Shareholders: Face significant uncertainty regarding the Company's stock listing, potential loss of liquidity if delisted, and potential negative impact on share value.

Next Steps

• Attend the hearing before Nasdaq's Hearings Panel on January 13, 2026.
• Await the Panel's decision regarding the Company's request for continued listing.
• If granted, work to regain and maintain compliance with Nasdaq's minimum bid price requirement.

Key Dates

Recommendation

The company faces a severe threat of delisting from Nasdaq due to non-compliance with the minimum bid price rule. While an appeal has temporarily stayed the delisting, there is no assurance of a favorable outcome or the ability to regain compliance. Delisting would severely impact liquidity and investor confidence, making the stock a high-risk proposition with significant downside potential. A seasoned investor would likely divest to avoid further exposure to this fundamental listing risk.

Keywords

Nasdaq, delisting, minimum bid price, compliance, veterinary, stock market, IVP, Inspire Veterinary Partners